Current Health Closes $11.5 Million Series A Funding Round
Investment will be used to scale the company’s patient management platform and enhance care delivery worldwide NEW YORK–(BUSINESS WIRE)–Current Health,…
Pharmaceuticals, Biotechnology and Life Sciences
Investment will be used to scale the company’s patient management platform and enhance care delivery worldwide NEW YORK–(BUSINESS WIRE)–Current Health,…
ABINGDON, England–(BUSINESS WIRE)–Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company developing population-based synthetic disease prophylaxis ‘set-point’ vaccines in the field…
TOKYO–(BUSINESS WIRE)–#CIPN–Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that it…
SCHLIEREN, Switzerland–(BUSINESS WIRE)–ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy…
Developed from being a university spin-off to become a medium-sized company with renowned customers from all over the world Order…
Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month…
The study achieved its primary objective of decitabine systemic exposure equivalence between oral ASTX727 and IV decitabine with an oral/IV…
Early evidence of clinical activity and robust safety findings highlighted SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Amphivena Therapeutics, Inc., a private clinical…
Company initiates Phase 1 clinical trial of Voriconazole Inhalation Powder, to treat invasive pulmonary aspergillosis (IPA) Successfully completes $24 million…
Updated data from the Phase 3 ALCYONE study demonstrated an overall survival benefit and continued improvement in progression-free survival after…